Article Information
History
- March 27, 2020.
Article Versions
- Version 1 (March 16, 2020 - 03:27).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Guangdong Medical University, Shenzhen Guangdong, China, E-mail: 15818662864{at}139.com
- 2Department of Hematology,Yi Chang Central People’s Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang Hubei, China, E-mail:gjm425{at}163.com
- 3Department of Hematology,Suizhou Central Hospital, Suizhou Hubei, China, E-mail:yzhzh88{at}163.com
- 4Department of Hematology, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science, Xiangyang Hubei, China
- 5Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan Hubei, China., E-mail: mengli{at}tjh.tjmu.edu.cn
- 6Department of Hematology, Union hospital, Tongji Medical college, Huazhong University of science and Technology, Wuhan Hubei, China., F-mail: lee937{at}126.com
- ↵*Correspondence author:
Guo-Lin Yuan, Department of Hematology, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science, Xiangyang Hubei, China., E-mail: yuanguo1973{at}163.com
Posted March 27, 2020.
The first report of the prevalence of COVID-19 in Chronic myelogenous leukemia patients in the core epidemic area of China: multicentre, cross-sectional survey
